Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.MRIC · Entity 2367 | Director | May 17, 2019 | May 17, 2019 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Chief Operating Officer | February 10, 2020 | February 12, 2020 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director · Chief Executive Officer | July 08, 2026 | July 08, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | August 25, 2022 | August 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date May 17, 2019 · Filed May 17, 2019
This filing explicitly reported no securities owned.
PTC THERAPEUTICS, INC.
Report date February 10, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 7,369 |
Reported balance
After 2020-02-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-10 · Exercise / conversion · Acquired 625 · Balance 7,369 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 6,744 |
Reported balance
After 2020-02-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-02-10 · Sale · Disposed 625 · Balance 6,744 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.92 · Expires 2027-05-17 | IndirectBy Spouse | 3,125 |
Reported balance
After 2020-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-10 · Exercise / conversion · Disposed 625 · Balance 3,125 F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. F2: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2028-01-02 | IndirectBy Spouse | 2,696 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2,696 F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.02 · Expires 2029-01-21 | IndirectBy Spouse | 6,825 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,825 F4: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.16 · Expires 2030-01-28 | IndirectBy Spouse | 4,170 |
Reported balance
Holding disclosure · report date 2020-02-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4,170 F5: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019.
F2: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018.
F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F4: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F5: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
Praxis Precision Medicines, Inc.
Report date July 08, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,495 |
Reported balance
After 2026-07-08 transaction · row 1
1 source rowRow 1 · 2026-07-08 · Gift · Disposed 20,521 · Balance 56,495 F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. |
| Common StockSEC Table I · non-derivative | IndirectHeld by spouse | 0 |
Reported balance
After 2026-07-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-08 · Gift · Disposed 2,600 · Balance 0 F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust.
Spyre Therapeutics, Inc.
Report date August 25, 2022 · Filed August 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,000 |
Reported balance
After 2022-08-25 transaction · row 1
1 source rowRow 1 · 2022-08-25 · Purchase · Acquired 90,000 · Balance 90,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 8, 2026 20:56 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GiftCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001707657-26-000008 · wk-form4_1783544160.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 0 F1 · kind: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. Read SEC document |
| July 08, 2026 Filed Jul 8, 2026 20:56 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GiftCommon Stock | 20,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001707657-26-000008 · wk-form4_1783544160.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,495 F1 · kind: This transaction represents a bona fide gift of common stock to the Souza 2026 Trust. Read SEC document |
| May 14, 2026 Filed May 20, 2026 01:42 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 126 | $167.94 | $21,160.82 |
DisclosureSEC source: 0001707657-26-000005 · wk-form4_1779241363.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,016 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2026 Filed Jan 12, 2026 22:48 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 4,252 | $288.45 | $1,226,489.40 |
DisclosureSEC source: 0001689548-26-000010 · wk-form4_1768258100.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,890 F2 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:48 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 22,110 | $0.00 Strike: $294.38 | $0.00 |
DisclosureSEC source: 0001689548-26-000010 · wk-form4_1768258100.xml · derivative · entry 4 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,110 Underlying: Common Stock · 22,110 shares Expires 2036-01-08 F3 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:48 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 27,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-26-000010 · wk-form4_1768258100.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,142 F1 · kind: Mr. Souza was awarded 27,640 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:46 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 405 | $292.63 | $118,515.15 |
DisclosureSEC source: 0001707657-26-000002 · wk-form4_1767995193.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,502 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| December 30, 2025 Filed Jan 1, 2026 00:17 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001707657-25-000004 · wk-form4_1767226660.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 2,600 F1 · kind: Shares were transferred as a gift to a charitable fund. Read SEC document |
| May 14, 2025 Filed May 19, 2025 20:57 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 348 | $31.54 | $10,974.18 |
DisclosureSEC source: 0001689548-25-000066 · wk-form4_1747688224.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,907 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:29 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 401 | $85.40 | $34,245.40 |
DisclosureSEC source: 0001689548-25-000025 · wk-form4_1739568557.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,559 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 23:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $63.15 | $0.00 |
DisclosureSEC source: 0001689548-25-000015 · wk-form4_1736898649.xml · derivative · entry 3 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-01-10 F2 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 10, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 23:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-25-000015 · wk-form4_1736898649.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,960 F1 · shares: Mr. Souza was awarded 37,500 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 10, 2025. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 00:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 434 | $77.52 | $33,643.68 |
DisclosureSEC source: 0001689548-25-000008 · wk-form4_1736383828.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,460 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| July 29, 2024 Filed Aug 1, 2024 01:03 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $56.94 | $0.00 |
DisclosureSEC source: 0001104659-24-084506 · tm2420554-4_4seq1.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-07-29 F1 · derivative.exercise_date: The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the reporting person's continued service through each vesting date. Read SEC document |
| May 14, 2024 Filed May 20, 2024 12:10 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 1,718 | $12.37 | $21,248.22 |
DisclosureSEC source: 0001689548-24-000063 · wk-form4_1716207004.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,894 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:10 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 271 | $44.65 | $12,100.15 |
DisclosureSEC source: 0001689548-24-000025 · wk-form4_1707945012.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,176 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:49 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0001689548-24-000020 · wk-form4_1705528185.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-12 F1 · derivative.exercise_date: The shares underlying this stock option vest as follows: 50% vested in full on January 12, 2024 (the "Grant Date") and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on the first anniversary of the Grant Date and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 07, 2024 Filed Jan 10, 2024 02:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 418 | $25.19 | $10,529.42 |
DisclosureSEC source: 0001689548-24-000006 · wk-form4_1704852568.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,447 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:52 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 10,000 | $1.06 | $10,587.00 |
DisclosureSEC source: 0001689548-23-000115 · wf-form4_168790990907113.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 45,001.75 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.045 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document |
| May 12, 2023 Filed May 19, 2023 01:47 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 11,687 | $0.88 | $10,331.31 |
DisclosureSEC source: 0001689548-23-000090 · wf-form4_168446079770828.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,986 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 17:12 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 35,001.75 | $0.86 | $30,206.51 |
DisclosureSEC source: 0001104659-23-037023 · tm2310645-3_4seq1.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 35,001.75 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8572 to $0.8676, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 17:12 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 35,000 | $0.86 | $30,159.50 |
DisclosureSEC source: 0001104659-23-037023 · tm2310645-3_4seq1.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,299 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.86 to $0.863, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 12:47 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 213,975 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001689548-23-000017 · wf-form4_167361403910614.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,975 Underlying: Common Stock · 213,975 shares Expires 2033-01-12 F1 · shares: Mr. Souza opted to receive this option grant in lieu of a cash bonus for the fiscal year ended December 31, 2022. Read SEC document |
| January 12, 2023 Filed Jan 18, 2023 00:34 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001689548-23-000026 · wf-form4_167400207336101.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2033-01-12 F1 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 12, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| November 14, 2022 Filed Nov 21, 2022 11:07 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 2,115 | $1.81 | $3,830.27 |
DisclosureSEC source: 0001689548-22-000131 · wf-form4_166902880883749.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,299 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 25, 2022 Filed Aug 25, 2022 23:37 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 90,000 | $0.56 | $50,472.00 |
DisclosureSEC source: 0001209191-22-047653 · doc4.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:45 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001689548-22-000089 · wf-form4_165610350532146.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 23:25 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 27,000 | $1.85 | $49,887.90 |
DisclosureSEC source: 0001689548-22-000076 · wf-form4_165481709561726.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,184 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.835 to $1.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 01:21 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035689 · doc4.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 13, 2022 Filed May 18, 2022 21:39 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 1,392 | $8.80 | $12,246.82 |
DisclosureSEC source: 0001689548-22-000044 · wf-form4_165290990575398.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,184 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 259,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001104659-22-003163 · tm222494-5_4seq1.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,000 Underlying: Common Stock · 259,000 shares Expires 2032-01-07 F2 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 7, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:09 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-003163 · tm222494-5_4seq1.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,792 F1 · shares: Mr. Souza was awarded 74,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on January 7, 2023, subject to the reporting person's continued service through each vesting date. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 22:33 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 9,542 | $15.79 | $150,668.18 |
DisclosureSEC source: 0001689548-21-000077 · wf-form4_162941239513679.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,792 Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:07 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $6.44 | $0.00 |
DisclosureSEC source: 0001209191-21-042377 · doc4.xml · derivative · entry 1 Souza Marcio · CIK 0001707657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on July 18, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 184,800 | $0.00 Strike: $52.53 | $0.00 |
DisclosureSEC source: 0001689548-21-000010 · wf-form4_161359893080474.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,800 Underlying: Common Stock · 184,800 shares Expires 2031-02-12 F2 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date of February 12, 2021 and the remaining 75% vesting in 36 equal monthly installments following such first anniversary, subject to the reporting person's continued service through each vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 52,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-21-000010 · wf-form4_161359893080474.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,250 F1 · shares: Mr. Souza was awarded 52,800 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of February 12, 2021. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 23:51 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | PurchaseCommon Stock | 3,846 | $26.08 | $100,303.68 |
DisclosureSEC source: 0000899243-20-030741 · doc4.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,450 Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | ConversionSeries C -1 Preferred Stock · Derivative | 44,092 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028742 · doc4.xml · derivative · entry 2 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,604 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C-1 Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: The Series C-1 Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: The Series C-1 Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:40 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | ConversionCommon Stock | 20,604 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-028742 · doc4.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C-1 Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 625 | $12.92 Strike: $12.92 | $8,075.00 |
DisclosureSEC source: 0001070081-20-000059 · wf-form4_158154174910694.xml · derivative · entry 3 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,125 Underlying: Common Stock · 625 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. F2 · derivative.exercise_date: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 625 | $53.92 | $33,700.00 |
DisclosureSEC source: 0001070081-20-000059 · wf-form4_158154174910694.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,744 F1 · kind: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 625 | $12.92 | $8,075.00 |
DisclosureSEC source: 0001070081-20-000059 · wf-form4_158154174910694.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 7,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted on November 19, 2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 4,170 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000043 · wf-form4_158050665977738.xml · derivative · entry 4 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,170 Underlying: Common Stock · 4,170 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 93,500 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000043 · wf-form4_158050665977738.xml · derivative · entry 3 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 93,500 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000043 · wf-form4_158050665977738.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,744 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000043 · wf-form4_158050665977738.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,097 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 154 | $53.25 | $8,200.04 |
DisclosureSEC source: 0001070081-20-000025 · wf-form4_158015969633865.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,074 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 481 RSUs from a January 22, 2019 grant of 1,925 RSUs. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 86 | $48.17 | $4,142.45 |
DisclosureSEC source: 0001070081-20-000014 · wf-form4_157852493768998.xml · nonDerivative · entry 2 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,228 F3 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 270 RSUs from a January 3, 2018 grant of 1,079 RSUs. F2 · balance_after: Includes 276 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2019. Read SEC document |
| December 30, 2019 Filed Jan 8, 2020 23:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000014 · wf-form4_157852493768998.xml · nonDerivative · entry 1 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,497 F1 · kind: Represents a charitable donation by the Reporting Person. F2 · balance_after: Includes 276 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 6,250 | $12.92 Strike: $12.92 | $80,750.00 |
DisclosureSEC source: 0001070081-19-000061 · wf-form4_157739905265156.xml · derivative · entry 17 Souza Marcio · CIK 0001707657 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,750 Underlying: Common Stock · 6,250 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · kind: The transactions of the Reporting Person's spouse reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on November 19, 2019. F14 · derivative.exercise_date: This option was granted on May 17, 2017, and vests over four years, with 25% of the shares underlying the option vesting on May 8, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on August 8, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.